Reflecting on a year defined by fluctuations in DTC healthcare, AI, and fragmented viewing environments, one key takeaway emerges — you’re only as good as your data. While many went deeper on AI, the importance of usable, clean, privacy-centric, and relevant data implemented responsibly and delivered across the ecosystem came to the fore. The foundation…

This article was originally published at Healthcare Business Today.   The White House’s recent memorandum directing the FDA to rein in direct-to-consumer (DTC) pharmaceutical advertising has reignited a long-running debate about the role of advertising in American health.  Despite the back and forth, the administration’s critics and proponents should agree that misleading ads are not beneficial. However, removing…

This content was originally published by DeepIntent.  Healthcare marketing is undergoing a transformation, with data-driven insights now serving as the foundation for how brands connect with consumers and providers. That’s why DeepIntent is excited to spotlight PurpleLab®, a data partner that’s helping pharmaceutical brands and agencies connect with their audiences in more effective and meaningful…

Biomarker testing can drastically extend survival across multiple cancer types. But gaps in adoption persist. Are payers, pharma and policymakers doing enough to ensure these tests actually having an impact in the real world? PurpleLab recently conducted a study, Maximizing Survival: The Real-World Impact of Biomarker Testing in Metastatic NSCLC, to shed light on how…

This article was originally posted in AdExchanger and written in collaboration with Natalie Mancuso from DeepIntent. Health care and life sciences have long lagged in digital advertising, still focused on mass-audience approaches. But as the blockbuster drug era fades and precision medicine rises, broad strategies often fail to make precision therapies commercially viable – leaving life-changing…

This article was originally published on MM+M.  Pharma advertising operates in an environment where complexity is the norm. As privacy rules tighten and identity-based targeting erodes, marketers often find themselves relying on fading signals, scanning limited dashboards and trying to overcome walled gardens. Meanwhile, impressions, reach and engagement metrics are indicators for success, but only…

As the healthcare industry continues to face data challenges, PurpleLab® is making significant investments in its data and infrastructure to reinforce its position as a trusted leader in real-world data (RWD). We’ve recently secured several new data sources that will dramatically improve the comprehensiveness and composition of our data.(RWD) and real-world evidence (RWE) earlier in the product lifecycle to inform decision-making.

Although randomized controlled trials remain a cornerstone of evidence generation, pharmaceutical and biotech companies are increasingly recognizing the necessity of leveraging real-world data
(RWD) and real-world evidence (RWE) earlier in the product lifecycle to inform decision-making.

Biomarker testing guides selection of targeted therapies in non–small cell lung cancer (NSCLC). Despite its clinical importance, the extent of provider variation in biomarker testing practices and its correlation with patient outcomes has not been thoroughly explored.